Coherus BioSciences (CHRS) Misses Q4 EPS by 19c
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.35 +9.76%
Revenue Growth %: +37.8%
Financial Fact:
Depreciation and amortization: 14.21M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: +37.8%
Financial Fact:
Depreciation and amortization: 14.21M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q4 EPS of $0.53, $0.19 worse than the analyst estimate of $0.72. Revenue for the quarter came in at $123.9 million versus the consensus estimate of $123.01 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Canaccord Starts L1 Group Ltd (L1G:AU) at Buy
- DraftKings Inc. (DKNG) PT Lowered to $48 at UBS on Updated Estimates Post Q2
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
